253 related articles for article (PubMed ID: 15139054)
1. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial.
Lara PN; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Kauderer C; Tichauer G; Twardowski P; Doroshow JH; Gandara DR
Cancer; 2002 May; 94(10):2584-9. PubMed ID: 12173324
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
Tedesco KL; Thor AD; Johnson DH; Shyr Y; Blum KA; Goldstein LJ; Gradishar WJ; Nicholson BP; Merkel DE; Murrey D; Edgerton S; Sledge GW
J Clin Oncol; 2004 Mar; 22(6):1071-7. PubMed ID: 15020608
[TBL] [Abstract][Full Text] [Related]
4. HER-2 profiling and targeting in prostate carcinoma.
Morris MJ; Reuter VE; Kelly WK; Slovin SF; Kenneson K; Verbel D; Osman I; Scher HI
Cancer; 2002 Feb; 94(4):980-6. PubMed ID: 11920466
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Krug LM; Miller VA; Patel J; Crapanzano J; Azzoli CG; Gomez J; Kris MG; Heelan RT; Pizzo B; Tyson L; Sheehan C; Ross JS; Venkatraman E
Cancer; 2005 Nov; 104(10):2149-55. PubMed ID: 16208701
[TBL] [Abstract][Full Text] [Related]
6. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
Gasparini G; Gion M; Mariani L; Papaldo P; Crivellari D; Filippelli G; Morabito A; Silingardi V; Torino F; Spada A; Zancan M; De Sio L; Caputo A; Cognetti F; Lambiase A; Amadori D
Breast Cancer Res Treat; 2007 Mar; 101(3):355-65. PubMed ID: 16850247
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Lara PN; Laptalo L; Longmate J; Lau DH; Gandour-Edwards R; Gumerlock PH; Doroshow JH; Gandara DR;
Clin Lung Cancer; 2004 Jan; 5(4):231-6. PubMed ID: 14967075
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
[TBL] [Abstract][Full Text] [Related]
10. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Coudert BP; Largillier R; Arnould L; Chollet P; Campone M; Coeffic D; Priou F; Gligorov J; Martin X; Trillet-Lenoir V; Weber B; Bleuse JP; Vasseur B; Serin D; Namer M
J Clin Oncol; 2007 Jul; 25(19):2678-84. PubMed ID: 17515572
[TBL] [Abstract][Full Text] [Related]
12. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.
Ziada A; Barqawi A; Glode LM; Varella-Garcia M; Crighton F; Majeski S; Rosenblum M; Kane M; Chen L; Crawford ED
Prostate; 2004 Sep; 60(4):332-7. PubMed ID: 15264245
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer.
Montemurro F; Choa G; Faggiuolo R; Donadio M; Minischetti M; Durando A; Capaldi A; Vietti-Ramus G; Alabiso O; Aglietta M
Oncology; 2004; 66(1):38-45. PubMed ID: 15031597
[TBL] [Abstract][Full Text] [Related]
14. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
15. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.
Dai GH; Shi Y; Chen L; Lv YL; Zhong M
Hepatogastroenterology; 2012; 59(120):2439-44. PubMed ID: 22534547
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
19. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
